Celcuity Inc.(CELC)

Biotechnology · Minneapolis, MN

$72.71-0.91 (-1.24%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

Celcuity (CELC) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T15:32:20.339Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:32:20.339Z.

Quote observation: 2026-10-06T15:31:20.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 3,565,059,484
Total debt · period ending 2026-06-30: 754,385,000
Cash · period ending 2026-06-30: 182,049,000
TTM operating EBITDA · period ending 2026-06-30: -208,479,000

FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CELC EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

CELC Competitors' EV/EBITDA Ratio

CELC

Celcuity Inc.

Current

Market Cap

$3.57B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IDYA

IDEAYA Biosciences, Inc.

vs CELC

Market Cap

$3.56B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IRTC

iRhythm Technologies, Inc.

vs CELC

Market Cap

$3.53B

EV/EBITDA Ratio

286.98x

TTM Avg

665.65x

3Y Avg

665.65x

5Y Avg

665.65x

ACAD

Acadia Pharmaceuticals Inc.

vs CELC

Market Cap

$3.45B

EV/EBITDA Ratio

31.87x

TTM Avg

29.77x

3Y Avg

69.20x

5Y Avg

69.20x

CDNA

CareDx, Inc

vs CELC

Market Cap

$3.44B

EV/EBITDA Ratio

198.02x

TTM Avg

115.31x

3Y Avg

72.49x

5Y Avg

72.49x

PLSE

Pulse Biosciences, Inc.

vs CELC

Market Cap

$3.40B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBLS

Parabilis Medicines, Inc.

vs CELC

Market Cap

$3.39B

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DNLI

Denali Therapeutics Inc.

vs CELC

Market Cap

$3.14B

EV/EBITDA Ratio

N/A

TTM Avg

116.71x

3Y Avg

116.71x

5Y Avg

116.71x

ICUI

ICU Medical, Inc.

vs CELC

Market Cap

$3.98B

EV/EBITDA Ratio

13.63x

TTM Avg

16.01x

3Y Avg

14.76x

5Y Avg

19.10x

AMLX

Amylyx Pharmaceuticals, Inc.

vs CELC

Market Cap

$3.11B

EV/EBITDA Ratio

N/A

TTM Avg

9.21x

3Y Avg

9.21x

5Y Avg

9.21x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Celcuity Inc. (CELC)	$3.57B	N/A	N/A	N/A	N/A
IDEAYA Biosciences, Inc. (IDYA)vs ›	$3.56B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.53B	286.98x	665.65x	665.65x	665.65x
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.45B	31.87x	29.77x	69.20x	69.20x
CareDx, Inc (CDNA)vs ›	$3.44B	198.02x	115.31x	72.49x	72.49x
Pulse Biosciences, Inc. (PLSE)vs ›	$3.40B	N/A	N/A	N/A	N/A
Parabilis Medicines, Inc. (PBLS)vs ›	$3.39B	N/A	N/A	N/A	N/A
Denali Therapeutics Inc. (DNLI)vs ›	$3.14B	N/A	116.71x	116.71x	116.71x
ICU Medical, Inc. (ICUI)vs ›	$3.98B	13.63x	16.01x	14.76x	19.10x
Amylyx Pharmaceuticals, Inc. (AMLX)vs ›	$3.11B	N/A	9.21x	9.21x	9.21x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics